Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: Latest evidence and therapeutic implications

Keyphrases

• Additional Therapy 33%
• Anti-programmed Cell Death Protein 1 33%
• Antivascular Therapy 33%
• Clinical Trials 33%
• Disease Biology 33%
• Disease Outcome 33%
• Disease Treatment 33%
• Drug Development 33%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 33%
• Further Development 33%
• Immune Checkpoint Inhibitors 33%
• Malignancy 33%
• New Therapies 33%
• Nivolumab 33%
• Renaissance 33%
• Renal Cancer 100%
• Resistance Pattern 33%
• Targeted Therapy 100%
• Therapeutic Implications 100%
• Treatment Resistance 33%
• Vascular Endothelial Growth Factor 100%
• Vascular Epidermal Growth Factor 33%

Medicine and Dentistry

• Cancer 33%
• Cancer Cell 100%
• Clinical Trial 33%
• Disease 66%
• Epidermal Growth Factor Receptor Kinase Inhibitor 33%
• Immune Checkpoint Inhibitor 33%
• Nivolumab 33%
• Programmed Death 1 Receptor 33%
• Targeted Therapy 100%
• Vasculotropin 100%